Skip to content
stoqly

Bioventus Inc.

BVS Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2019–FY2025

Revenue Total sales reported in the income statement.
$568M
0.9% vs prior year
Operating margin Operating income as a share of revenue.
9.5%
12.2 pts
Net income Profit after all expenses, interest and tax.
$22.7M
Free cash flow Cash from operations minus capital spending.
$72.1M
90.8%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
12.6%
15.4 pts
Market cap Last close times the latest diluted share count, so it is approximate.
—
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On $0.77 EPS (TTM)

What Bioventus Inc. does

No business description yet.

Legal name
Bioventus Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Mar 5, 2026
Accession · CIK
0001665988-26-000011
0001665988

Revenue and margins

Bioventus Inc. had $568M of revenue in fiscal 2025, down 0.9% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $72.1M in fiscal 2025, 12.7% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Bioventus Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 6.8%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Bioventus Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $43.9M$30.2M$37.0M$41.6M$51.2M
Debt incl. finance leases $358M$418M$406M$346M$304M
Net debt / EBITDA 6.7x——8.9x2.5x
Debt / equity 0.8x1.3x2.3x2.3x1.6x
Current ratio 1.5x0.9x1.5x1.3x1.7x
Quick ratio 1.1x0.6x1.0x0.9x1.2x
Total assets $1.2B$1.4B$811M$728M$684M
Total liabilities $618M$960M$590M$542M$455M
Shareholders' equity $459M$325M$174M$148M$184M
Net debt (− = net cash) $314M$388M$369M$304M$252M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY19FY20FY21FY22FY23FY24FY25
Net income is positive ✓ ✓ ✓ ✕ ✕ ✕ ✓
Cash from operations is positive ✓ ✓ ✓ ✕ ✓ ✓ ✓
Return on assets rose — — ✕ ✕ ✕ ✓ ✓
Cash from operations exceeds net income ✓ ✓ ✓ ✓ ✓ ✓ ✓
Debt fell relative to assets — — ✓ ✕ ✕ ✓ ✓
Current ratio rose — — ✕ ✕ ✓ ✕ ✓
Share count didn't rise — — — ✕ ✕ ✕ ✕
Gross margin rose — ✕ ✕ ✕ ✕ ✓ ✓
Revenue rose relative to assets — — ✕ ✓ ✓ ✓ ✓
F-score — / 3— / 44 / 82 / 94 / 96 / 98 / 9
Accruals ratio —−11.2%−0.4%−11.2%−15.7%−9.7%−7.4%
Altman Z'' ——1.27−1.01−0.91−0.870.44

7 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $340M $321M $431M $512M $512M $573M $568M
Gross profit $249M $234M $303M $331M $328M $388M $388M
Research and development $11.1M $11.2M $19.0M $23.9M $13.4M $14.0M $12.1M
Operating income $31.2M $21.2M $12.1M −$167M −$81.7M −$15.2M $54.0M
Pretax income $9.7M $15.9M $9.5M −$189M −$121M −$52.3M $25.7M
Income tax $1.6M $1.2M −$2.0M −$44.4M $0.1M −$5.3M −$1.6M
Net income $6.9M $16.4M $19.4M −$159M −$156M −$36.1M $22.7M
Net income to common — — — −$159M — — —
Diluted EPS — — −$0.15 −$2.59 −$2.49 −$0.56 $0.33
Diluted shares — — 0.05B 0.06B 0.06B 0.06B 0.07B
Cash flow
Cash from operations $40.7M $71.8M $23.0M −$13.5M $15.3M $38.8M $74.7M
Capital expenditure $2.3M $16.6M $13.5M $1.5M $7.4M $1.0M $2.6M
Free cash flow $38.4M $55.2M $9.5M −$15.0M $8.0M $37.8M $72.1M
Depreciation and amortization $30.3M $28.6M $34.9M $55.4M $57.4M $49.6M $47.0M
Stock-based compensation $0.0M $0.0M $19.8M $17.6M $2.7M $13.3M $12.7M
Acquisitions −$0.4M $0.0M $263M — — — —
Balance sheet
Cash and short-term investments $64.5M $86.8M $43.9M $30.2M $37.0M $41.6M $51.2M
Total debt — $188M $358M $418M $395M $336M $294M
Finance lease liabilities — — — $0.1M $11.1M $10.4M $9.6M
Current assets — $212M $263M $273M $268M $276M $273M
Current liabilities — $123M $181M $304M $175M $210M $160M
Inventory — $29.1M $61.7M $84.8M $91.3M $92.5M $82.2M
Property and equipment, net — $6.9M $23.0M $27.6M — — —
Goodwill — $49.8M $148M $7.5M $7.5M $7.5M $7.5M
Intangible assets — $192M $695M $640M $482M $405M $368M
Total assets — $494M $1.2B $1.4B $811M $728M $684M
Total liabilities — $350M $618M $960M $590M $542M $455M
Shareholders' equity — — $459M $325M $174M $148M $184M
Margins
Gross margin 73.3% 72.7% 70.3% 64.6% 64.1% 67.7% 68.3%
Operating margin 9.2% 6.6% 2.8% −32.7% −16.0% −2.7% 9.5%
EBITDA margin 18.1% 15.5% 10.9% −21.8% −4.8% 6.0% 17.8%
Net margin 2.0% 5.1% 4.5% −31.0% −30.5% −6.3% 4.0%
FCF margin 11.3% 17.2% 2.2% −2.9% 1.6% 6.6% 12.7%
Returns
Return on capital — — 1.6% −18.5% −12.1% −2.7% 12.6%
Return on capital employed — 5.7% 1.2% −15.6% −12.9% −2.9% 10.3%
Return on equity — — 4.2% −40.5% −62.6% −22.5% 13.7%
Return on assets — 3.3% 2.3% −12.2% −14.3% −4.7% 3.2%
Growth
Revenue growth — −5.6% 34.2% 18.8% 0.0% 11.9% −0.9%
Net income growth — 139.5% 18.1% −919.1% — — —
FCF growth — 43.9% −82.8% −258.5% — 373.4% 90.8%
Share count change — — — 35.0% 2.1% 3.0% 6.8%
Financial health
Net debt / EBITDA — 2.0x 6.7x — — 8.9x 2.5x
Debt / equity — — 0.8x 1.3x 2.3x 2.3x 1.6x
Current ratio — 1.7x 1.5x 0.9x 1.5x 1.3x 1.7x
Quick ratio — 1.5x 1.1x 0.6x 1.0x 0.9x 1.2x
Capital allocation
Capex / revenue 0.7% 5.2% 3.1% 0.3% 1.4% 0.2% 0.5%
Stock comp / revenue 0.0% 0.0% 4.6% 3.4% 0.5% 2.3% 2.2%
Quality scores
Piotroski F-score — — 4.0 2.0 4.0 6.0 8.0
Altman Z'' — — 1.3 −1.0 −0.9 −0.9 0.4
Accruals ratio — −11.2% −0.4% −11.2% −15.7% −9.7% −7.4%

Source: SEC EDGAR XBRL filings (CIK 0001665988). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open